Literature DB >> 31961720

Protective role of cardiac-specific overexpression of caveolin-3 in cirrhotic cardiomyopathy.

So Yeon Kim1, Kang Ho Kim2, Jan M Schilling3, Joseph Leem3, Mehul Dhanani3, Brian P Head3, David M Roth3, Alice E Zemljic-Harpf3, Hemal H Patel3.   

Abstract

Cirrhotic cardiomyopathy is a clinical syndrome in patients with liver cirrhosis characterized by blunted cardiac contractile responses to stress and/or heart rate-corrected QT (QTc) interval prolongation. Caveolin-3 (Cav-3) plays a critical role in cardiac protection and is an emerging therapeutic target for heart disease. We investigated the protective role of cardiac-specific overexpression (OE) of Cav-3 in cirrhotic cardiomyopathy. Biliary fibrosis was induced in male Cav-3 OE mice and transgene negative (TGneg) littermates by feeding a diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC; 0.1%) for 3 wk. Liver pathology and blood chemistries were assessed, and stress echocardiography, telemetry, and isolated heart perfusion studies to assess adrenergic responsiveness were performed. Cav-3 OE mice showed a similar degree of hyperdynamic contractility, pulmonary hypertension, and QTc interval prolongation as TGneg mice after 3 wk of DDC diet. Blunted systolic responses were shown in both DDC-fed Cav-3 OE and TGneg hearts after in vivo isoproterenol challenge. However, QTc interval prolongation after in vivo isoproterenol challenge was significantly less in DDC-fed Cav-3 OE hearts compared with DDC-fed TGneg hearts. In ex vivo perfused hearts, where circulatory factors are absent, isoproterenol challenge showed hearts from DDC-fed Cav-3 OE mice had better cardiac contractility and relaxation compared with DDC-fed TGneg hearts. Although Cav-3 OE in the heart did not prevent cardiac alterations in DDC-induced biliary fibrosis, cardiac expression of Cav-3 reduced QTc interval prolongation after adrenergic stimulation in cirrhosis.NEW & NOTEWORTHY Prevalence of cirrhotic cardiomyopathy is up to 50% in cirrhotic patients, and liver transplantation is the only treatment. However, cirrhotic cardiomyopathy is associated with perioperative morbidity and mortality after liver transplantation; therefore, management of cirrhotic cardiomyopathy is crucial for successful liver transplantation. This study shows cardiac myocyte specific overexpression of caveolin-3 (Cav-3) provides better cardiac contractile responses and less corrected QT prolongation during adrenergic stress in a cirrhotic cardiomyopathy model, suggesting beneficial effects of Cav-3 expression in cirrhotic cardiomyopathy.

Entities:  

Keywords:  adrenergic; caveolin; cirrhotic cardiomyopathy

Mesh:

Substances:

Year:  2020        PMID: 31961720      PMCID: PMC7099497          DOI: 10.1152/ajpgi.00346.2019

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  45 in total

Review 1.  Caveolins in cardioprotection - translatability and mechanisms.

Authors:  Jan M Schilling; David M Roth; Hemal H Patel
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

2.  Echocardiography in Mice.

Authors:  Shumin Gao; David Ho; Dorothy E Vatner; Stephen F Vatner
Journal:  Curr Protoc Mouse Biol       Date:  2011-03-01

3.  Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis.

Authors:  Moreshwar S Desai; Zainuer Shabier; Michael Taylor; Fong Lam; Sundararajah Thevananther; Astrid Kosters; Saul J Karpen
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

4.  Cardiac alterations in cirrhosis: reversibility after liver transplantation.

Authors:  Mireia Torregrosa; Santi Aguadé; Laura Dos; Rosa Segura; Antonio Gónzalez; Artur Evangelista; Joan Castell; Carlos Margarit; Rafael Esteban; Jaume Guardia; Joan Genescà
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

5.  Electrophysiology and metabolism of caveolin-3-overexpressing mice.

Authors:  Jan M Schilling; Yousuke T Horikawa; Alice E Zemljic-Harpf; Kevin P Vincent; Leonid Tyan; Judith K Yu; Andrew D McCulloch; Ravi C Balijepalli; Hemal H Patel; David M Roth
Journal:  Basic Res Cardiol       Date:  2016-03-29       Impact factor: 17.165

6.  Noninvasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension.

Authors:  Hélène B Thibault; Baptiste Kurtz; Michael J Raher; Rahamthulla S Shaik; Aaron Waxman; Geneviève Derumeaux; Elkan F Halpern; Kenneth D Bloch; Marielle Scherrer-Crosbie
Journal:  Circ Cardiovasc Imaging       Date:  2009-12-31       Impact factor: 7.792

7.  Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats.

Authors:  Z Ma; A Miyamoto; S S Lee
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

Review 8.  Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development.

Authors:  Bénédicte Delire; Peter Stärkel; Isabelle Leclercq
Journal:  J Clin Transl Hepatol       Date:  2015-03-15

9.  Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population.

Authors:  Jonas B Nielsen; Claus Graff; Peter V Rasmussen; Adrian Pietersen; Bent Lind; Morten S Olesen; Johannes J Struijk; Stig Haunsø; Jesper H Svendsen; Lars Køber; Thomas A Gerds; Anders G Holst
Journal:  Eur Heart J       Date:  2014-03-06       Impact factor: 29.983

10.  QT prolongation is associated with increased mortality in end stage liver disease.

Authors:  Sun Moon Kim; Bennet George; Diego Alcivar-Franco; Charles L Campbell; Richard Charnigo; Brian Delisle; Jonathan Hundley; Yousef Darrat; Gustavo Morales; Samy-Claude Elayi; Alison L Bailey
Journal:  World J Cardiol       Date:  2017-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.